Nobel dinner 2025 😊

Whole-genome sequencing reveals three follicular lymphoma subtypes with distinct cell of origin and patient outcomes Using whole-genome and transcriptomic sequencing, Ren et al. identify three clinically relevant genetic subtypes of follicular lymphoma. These subtypes are defined by distinct mutation profiles, mutat...

New paper from us 😊.Through WGS, we identified three clinically relevant molecular subtypes of follicular lymphoma, with distinct mutational patterns, transcriptional profiles, cell-of-origin characteristics, and clinical outcome www.cell.com/cell-reports...

Monoallelic expression in human immune cells: linking genotype to phenotype Patients with an inborn error of immunity (IEI) often show a complete penetrance of their disease-causing mutation, whereas other forms of IEI show a …

Our latest paper discusses the interesting findings by Bogunovic and colleagues: www.sciencedirect.com/science/arti...

The Crafoord Prize in Polyarthritis 2025 Christopher Goodnow and David Nemazee discovered mechanisms that prevent autoimmune disease.

Congratulations to Christopher Goodnow and David Nemazee on winning the 2025 Crafoord Prize! Their groundbreaking research has brought B cells back to the spotlight, deepening our understanding of autoimmunity. www.crafoordprize.se/news/crafoor...

The 1st IEI-Hema EU rare disease consortium meeting in beautiful Florence! Explore the “other side of coin” in Immune and Blood Disorders. Thanks everyone for the great meeting, especially @elegambis.bsky.social #Europen joint program for rare diseases #PID #IEI #hematology

JHI Editor-in-Chief Jean-Laurent Casanova @casanovalab.bsky.social is a professor at The Rockefeller University and a Howard Hughes Medical Institute Investigator https://www.hgid.org

Learn more about Journal of Human Immunity 📗 https://buff.ly/4ajqm8W

Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants | Journal of Virology The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) JN.1 strain, which became globally predominant in the first half of 2024, has an additional L455S mutation in its receptor-binding domain compared to its precursor, BA.2.86, enhancing its ability to evade immune responses (1–3). Some subvariants derived from JN.1, such as KP.2 and KP.3, exhibit even greater immune escape abilities (4, 5). The reduced antibody response to JN.1 and its derivative variants is likely responsible for the increase in infections and hospitalizations in summer 2024 (6). Given concerns about immunological imprinting and the lack of an effective mucosal vaccine (7), administering cross-reactive monoclonal antibodies (mAbs) at the mucosal surface as pre-exposure prophylaxis may offer alternative protection.

We engineered ultrapotent IgA antibodies, derived from cross-reactive neutralizing IgG, originally isolated from a SARS-CoV-2-vaccinated and SARS-CoV-1 convalescent donor. Still work nicely against all Omicron variants! journals.asm.org/doi/full/10....

Nobel concert 2024